Kenneth Hillan
2021
In 2021, Kenneth Hillan earned a total compensation of $3.2M as Chief Therapeutics Officer at 23andMe Holding Co..
Compensation breakdown
| Option Awards | $2,671,454 |
|---|---|
| Salary | $554,960 |
| Other | $2,658 |
| Total | $3,229,072 |
Hillan received $2.7M in option awards, accounting for 83% of the total pay in 2021.
Hillan also received $555K in salary and $2.7K in other compensation.
Rankings
In 2021, Kenneth Hillan's compensation ranked 4,147th out of 12,406 executives tracked by ExecPay. In other words, Hillan earned more than 66.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,147 out of 12,406 | 67th |
Division Manufacturing | 1,707 out of 5,492 | 69th |
Major group Chemicals And Allied Products | 706 out of 2,368 | 70th |
Industry group Drugs | 628 out of 2,089 | 70th |
Industry Pharmaceutical Preparations | 442 out of 1,536 | 71st |
Source: SEC filing on July 15, 2022.
Hillan's colleagues
We found three more compensation records of executives who worked with Kenneth Hillan at 23andMe Holding Co. in 2021.